Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies & High-Value Diagnostics 2015

Chamindie Punyadeera's Biography

Chamindie Punyadeera, Associate Professor, Institute of Health and Biomedical Innovation, Queensland University of Technology

Associate Professor Chamindie Punyadeera is an entrepreneur with a track record in innovation, industry engagement, intellectual property generation, and business development. She is a globally acknowledged pioneer in salivary diagnostics. She obtained her Ph.D. in Clinical Chemistry from the University of Witwatersrand, South Africa, prior to undertaking postdoctoral training with Professor Ton de Goeij, at the University of Masstricht, The Netherlands. She subsequently joined Royal Philips Electronics, Eindhoven, The Netherlands, as a Senior Scientist/Project Leader. Currently she heads the Saliva Translational Research (STaR) laboratory at the Queensland University of Technology, Australia. Her team focuses on developing novel diagnostic and prognostic biomarkers for cardiovascular diseases, head and neck cancers and linking oral health to systemic diseases. She has collaborative projects with Johnson & Johnson, MDx-health, Mawi-DNA Technologies and Oasis Diagnostics, is a consultant to Oasis Diagnostics® and FLUIDS iQ™. She has 13 PCT patents and over 60 refereed publications, including 4 invited book chapters, and serves on the Editorial Board of the Journal of Oral Oncology and the Associate Editor to the Journal of Dento Medical Science.

Chamindie Punyadeera Image

Oral and Oropharyngeal Cancer Detection is Spitting Distance Away

Tuesday, 17 November 2015 at 12:00

Add to Calendar ▼

Oral (OC) and oropharyngeal cancers (OPC) are significantly fatal; only approximately 50% of patients survive to 5 years. Surgery and chemoradiotherapy can leave survivors with pain, disfigurement and disability that further add to the burden of the disease. Unfortunately, more than half of these cancers are only diagnosed at an advanced stage, at which stage their 5-year survival rate plummets. Therefore, there is an urgent need for a reliable early diagnostic method. Current diagnosis is usually made after clinical presentation based on symptoms from the primary cancer and/or when metastatic cervical lymph nodes become obvious. Diagnosis involves biopsy identification of Human Papilloma Virus (HPV) status and histological classification. These diagnostic methods are subjective and become problematic when tumours are too small to be visualised or they are cryptic. These issues commonly result in misdiagnosis. The direct contact between saliva and OC and OPC lesions make the measurement of tumour markers in saliva an attractive alternative to serum and tumour tissue testing.

Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonBiofluid Biopsies and High-Value Diagnostics 2015Biofluid Biopsies and High-Value Diagnostics 2015 in Boston, USABoston,